Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2013 | 01:06pm CET
   By Saabira Chaudhuri 
 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
01/26 BIOGEN : Reports 2016 Revenues of $11.4 Billion
01/23BIOGEN INC : annual earnings release
01/17 BIOGEN FOURTH QUARTER AND YEAR END 2 : 00 am on January 26, 2017
01/17 SIEMENS HEALTHINEERS : and Biogen Announce Agreement to Jointly Develop New MRI ..
01/17DJBIOGEN : Reaches Settlement and License Agreement for MS Drug
More news
Sector news : Biopharmaceuticals
08:48aDJBAYER : Investors Upbeat on Takeover -- WSJ
03:32a Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/20DJBAYER : Trump Backing for Bayer's Monsanto Deal Buoys Investors
02/20DJBAYER : 4Q 2016 -- Forecast
02/20DJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
More sector news : Biopharmaceuticals
News from SeekingAlpha
02/20 Tracking John Paulson's Paulson & Company Portfolio - Q4 2016 Update
02/19 Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2016 Update
02/17 Can Anything Be Learned From Alzheimer's Drug Failures?
02/17 Celgene's ozanimod successful in late-stage MS study; shares up a fraction pr..
02/16 Verubecestat Halt Fails To Stop The Bace Chase
Advertisement
Financials ($)
Sales 2017 11 287 M
EBIT 2017 6 114 M
Net income 2017 3 973 M
Debt 2017 610 M
Yield 2017 -
P/E ratio 2017 15,61
P/E ratio 2018 13,93
EV / Sales 2017 5,58x
EV / Sales 2018 5,13x
Capitalization 62 397 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 322 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC10.56%62 397
CSL LIMITED19.78%41 842
ALEXION PHARMACEUTICAL..5.29%28 935
BIOMARIN PHARMACEUTICA..8.49%15 457
GRIFOLS SA11.81%14 012
3SBIO INC2.63%2 538
More Results